Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Droxidopa”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 217 records · Page 12Linked to original sources

[An elderly case of hypertension with persistent orthostatic hypotension].

The authors report the successful control of labile hypertension associated with orthostatic hypotension in a 75-year-old male patient, by means of L-DOPS, a synthetic precursor of norepinephrine in combination with antihypertensive drugs. He had been known to be hypertensive for 15 years and developed a persistent floating sensation 2 years age. Despite good control of hypertension after admission, orthostatic hypotension was still observed. Passive tilt produced a blood pressure reduction of 60/20 mmHg. Spectral analysis of heart rate variability showed a disturbance in the activation of the sympathetic nervous system. Treatment with L-DOPS attenuated the blood pressure reduction in response to passive tilt (35/12 mmHg) and improved the sympathetic response. Because of an increase in blood pressure by L-DOPS, addition of either a calcium channel blocker or an angiotensin-converting enzyme inhibitor was necessary. These combinations of treatment successfully controlled blood pressure as well as orthostatic hypotension.

Aged↗

[A case of "pure" progressive autonomic failure in an elderly male].

A 68-year-old man was admitted to our hospital because of postural hypotension in July 1991. He was also suffering from anhydrosis, urinary disturbances, constipation and impotence. He had not developed signs of Parkinsonism, cerebellar or peripheral neuropathy four years from the onset. Various autonomic function tests showed sympathetic and parasympathetic dysfunction of mainly postganglionic origins. Thus we diagnosed this patient as "pure" progressive autonomic failure ("pure" PAF). "Pure" PAF is a new entity described by Bannister and Oppenheimer in 1982. It shows symptoms of autonomic failure without other neurological disturbances which manifest as Shy-Drager syndrome. Treatment with L-DOPS increased his blood pressure level and attenuated his symptoms due to orthostatic hypotension.

Aged↗

Effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) on catecholamine levels in plasma and cerebrospinal fluid (CSF) in anesthetized rats.

The effect of L-threo-3,4-dihydroxyphenylserine (L-DOPS) on norepinephrine (NE) levels in plasma and CSF was examined in urethane-anesthetized rats. Intravenous injection of L-DOPS (0.5, 1, and 10 mg/100 g body wt) raised plasma NE levels in a dose-related manner whereas CSF NE levels were significantly increased only by the largest dose of L-DOPS. Intracerebroventricular injection of L-DOPS (50 and 250 micrograms/rat) dose-relatedly raised CSF NE levels whereas plasma NE levels were slightly increased by a larger dose of L-DOPS. These findings may indicate that L-DOPS stimulates central noradrenergic mechanisms in the rat although a large dose of L-DOPS is required for peripheral administration.

Animals↗

[Noradrenaline synthesis during the first week of life and development of inherited stress-induced arterial hypertension in rats].

Increasing of the noradrenaline synthesis with daily i.p. administration of synthetic noradrenaline precursor DL-Threo on the 21-25th day of life of the rats with inherited stress-induced arterial hypertension (ISIAH) resulted in a drop of basal and stress-induced blood pressure in adult animals with no changes in response of the hypothalamic-pituitary-adrenocortical system (HPAS). Reduction of the noradrenaline synthesis with daily i.p. administration of dopamine-hydroxylase inhibitor FLA-57 in 21-25th day old Wistar rats induced no arterial hypertension in adults but decreased their adrenocortical response to emotional stress. Noradrenaline deficit in the brain structures on the 4th week of life in rats seems to be associated with arterial hypertension only in presence of genetic defect determining this pathology. Changes in adult HPAS function due to shortage of noradrenaline in the brain in the end of the 1st month of life do not depend on hypertension.

Animals↗

The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine.

The action of the four stereoisomers of 3,4-dihydroxyphenylserine (DOPS) on the monoamine content of brain and heart was investigated with biochemical and histochemical methods. The (+)-erythro-DOPS (50-250 mg/kg i.p.), due to its alphaS configuration, was readily decarboxylated in vivo leading to an accumulation of norepinephrine (NE) in brain and heart. The amino probably corresponded to the unnatural (+) form since the amino acid shows betaS configuration. The NE was located in brain regions rich in noradrenergic (hypothalamus, locus ceruleus), dopaminergic (neostriatum, substantia nigra) and 5-hydroxytryptaminergic (raph'e nuclei) neurons. In addition, (+)-erythro-DOPS decreased the level of endogenous 5-hydroxytryptamine and dopamine and increased that of 5-hydroxyindoleacetic and homovanillic acid in the brain indicating a displacement of 5-hydroxytryptamine and dopamine, respectively, from their storage sites. Inhibitors of extracerebral decarboxylase (benserazid and carbidopa) diminished the (+)-erythro-DOPS-induced increase in cerebral NE by inhibiting the decarboxylation of the amino acid in the walls of the brain capillaries. The (-)-threo-DOPS, which also show alphaS configuration, was decarboxylated too, leading to a rise in cardiac NE. The amine was likely to correspond to the natural(-)-isomer since (-)-threo-DOPS has betaR configuration. This increase in NE lasted much longer than that caused by (+)-erythro-DOPS. In the brain, the accumulation of NE was negligible after i.p. administration of (-)-threo-DOPS but marked after injection of the isomer into a cerebral ventricle indicating a poor penetration of (-)-threo-DOPS through the blood-brain barrier. High doses (500 and 1000 mg/kg i.p.) of (-)-erythro- and (+)-threo-DOPS caused only a slight increase in cerebral and cardiac NE since, due to their alphaR configuration, they were probably not decarboxylated to a major extent. In conclusion, (+)-NE formed from (+)-erythro-DOPS probably accumulates in the storage sites of the endogenous monoamines where it might function as a false neurotransmitter.

Animals↗

[Synthesis of norepinephrine from 3,4-dihydroxyphenylserine by L-aromatic amino acid decarboxylase of the rat brain and kidneys].

The enzymic decarboxylation of stereoisomers of DOPS was examined using rat brain and kidney decarboxylase. Optimal assay conditions for racemic threo- and racemic erythro-DOPS decarboxylation were determined by the experiments concerning 1) time course, linear for 20 min, 2) optimal pH, pH 8.2, 3) optimal temperature, 37 degrees C except racemic L-threo-DOPS decarboxylation by kidney enzyme and 4) protein concentration, 1 to 5 mg in incubation medium. Under the optimal assay condition, Km of brain enzyme for L-threo-DOPS was 1.43 X 10(-3)M and Vmax, 2.22 nmoles NE/mg/15min, and Km for racemic erythro-DOPS was 10(-3)M and Vmas, 4.3 nmoles NE/mg/15min. Km of kidney enzyme for L-threo-DOPS was 1.37 X 10(-3)M and Vmax 21 nmoles NE/mg/15min, and Km for racemic erythro-DOPS was 8.7 X 10(-4)M and Vmax, 16.7 nmoles NE/mg/15min. On the other hand, D-threo and D-erythro-DOPS were scarcely decarboxylated. Decarboxylation of L-threo-DOPS in kidney enzyme was markedly inhibited by D-threo-DOPS. Kinetic analysis revealed that the type of inhibition was non-competitive. In helically-cut strips of isolated rabbit aorta, the contractile response to NE (10(-8)g/ml) formed from L-threo-DOPS was 95% that of 1-NE (10(-8)g/ml) while the response to NE (10(-8)g/ml) formed from racemic erythro-DOPS was not detectable. These results suggest that L-threo-DOPS is a more effective precursor of natural 1-NE than racemic threo-DOPS.

Animals↗

[A case of progressive supranuclear palsy dramatically improved with L-threo-3,4-dihydroxyphenylserine].

We report a 67-year-old female with progressive supranuclear palsy (PSP) who dramatically improved when given L-threo-3,4-dihydroxyphenylserine (L-DOPS). This patient developed dysarthria, lack of facial expression, and slowness at age 64. She was admitted to a local hospital, diagnosed as having parkinsonism and treated with antiparkinsonian drugs. Despite this treatment, she had difficulty in turning over in bed and standing up from a seat, and began to fall backward at age 65. One year later, she had trouble in walking due to frequent falls and became bedridden. The patient was admitted to our hospital in July 1991 under treatment with 20 mg/200 mg of carbidopa/L-dopa and 4 mg of trihexyphenydyl hydrochloride per day. Neurological examination revealed masked face, pseudobulbar palsy, and dystonic rigidity of the neck and upper trunk. Eye movements were normal except for impaired vertical saccades and convergence inability. Deep tendon reflexes were generally brisk and the plantar responses were flexor bilaterally. Tests of pulsion showed that her postural reflex was markedly disturbed, especially in retropulsion. Her gait showed severe unsteadiness. Neuropsychological tests showed intellectual impairment, frontal lobe dysfunction, and memory disturbance. Computed tomography showed an atrophic midbrain with prominent enlargement of ambient and quadrigeminal plate cisterns. Single photon emission computed tomography (SPECT) using 123-I-isopropyl-iodoamphetamine demonstrated marked frontal hypoperfusion. L-DOPS was administered at a dose of 100 mg per day and gradually increased up to 600 mg per day over a period of five weeks, while carbidopa/L-dopa and trihexyphenidyl hydrochloride were continued as on admission.(ABSTRACT TRUNCATED AT 250 WORDS)

Aged↗

[Pure akinesia presenting with antecollis].

We reported a 77-year-old woman having pure akinesia who presented with antecollis induced by L-threo-3, 4-dihydroxyphenylserine (L-DOPS). At the age of 70, she noticed increasing difficulty in standing up from a seat and moving. Afterward, she developed gait disturbance with difficulty in initiating walking, frozen gait, and postural instability. At 73 years of age, she came to our hospital, because she gradually fell down easily. Neurological examination disclosed mild akinesia with freezing symptom and kinésie paradoxale. No evidence of dementia, supranuclear gaze palsy, pseudobulbar palsy, rigidity, or tremor were present. As she developed akinesia, of which L-dopa therapy achieved little improvement, we clinically diagnosed as having pure akinesia. At age 74, L-DOPS was administered at a dose of 300mg per day and gradually increased up to 900mg per day, because her postural reflex was markedly disturbed and gait showed severe unsteadiness. Amelioration of frozen gait and unsteadiness were recognized, but efficacy of L-DOPS was temporal. It is well known that reported cases of pure akinesia were pathologically diagnosed as having progressive supranuclear palsy (PSP) or pallido-nigro-luysian atrophy. Therefore, the present case was suspected as having pathological changes which involved degeneration of the substantia nigra and globus pallidus. After three years of treatment with L-DOPS, at age 77, she was admitted to our hospital for abrupt onset of her dropped head. Hematological examinations were normal, cervical MRI showed no evidence of paracervical muscular atrophy, and electromyography did not demonstrate any abnormal change. In addition, her posterior cervical muscles showed abnormally high tension, so the dropped head was considered due to antecollis. After admission, antecollis disappeared rapidly following discontinuation of L-DOPS. However the mechanism of drug induced dystonia is imperfectly understood on the basis of the clinical course, L-DOPS was considered as possible cause of her antecollis. L-DOPS, artificial precursor of noradrenarine (NA), is thought to increase not only NA level in the CNS, but also inhibit release of acetylcholine. It is suggested that the antecollis of present case results from impairment of a normal dopaminergic-noradorenergic balance caused by increased NA and striatal dopamine deficiency. This is the first case of antecollis induced by L-DOPS in a pure akinesia patient, providing important information on mechanism of drug induced dystonia and indicating caution in the clinical use of L-DOPS.

Aged↗

Evaluation of the role of noradrenaline precursor on LH release induced by ovarian steroids.

The role of noradrenaline precursor on the release of luteinizing hormone-releasing hormone based on the plasma concentration of luteinizing hormone (LH) was studied in rats. Rats were ovariectomized at 1000h on diestrus day 1(D1) and primed with estradiol immediately after the operation. They received progesterone at 0930h in the next morning (the expected diestrus day 2, D2). Dynamic changes of plasma LH levels were examined in the afternoon of D2. Treatments and results are as follows: 1) Administration of DL-threo-dihydroxyphenylserine (DOPS, 200mg/kg BW, ip) at 0900h on D2, 30 min prior to progesterone treatment, results in 87.5% of rats showing LH surges. 2) Administration of 5-hydroxytryptophan (5-HTP, 100mg/kg BW, ip) 30 min before DOPS completely inhibits the action of DOPS on LH release induced by ovarian steroids. 3) Making a change of the whole working schedule of operation, estrogen was given 5 hours earlier on D1. DOPS and progesterone were given at 0500 hand 0530 h on D2, respectively. It does not induce the LH surge during the whole morning of D2. These results demonstrate that DOPS might just reduce the threshold of the central neurons governing LH release. The time in a fixed lighting schedule was important in determining the LH release induced by ovarian steroids.

5-Hydroxytryptophan↗

[Analysis of L-threo-3, 4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease].

Improvement of motor and psychological symptoms by L-DOPS (L-threo-3,4-dihydroxyphenylserine) in totally 20 cases with Parkinson's disease (PD), including 5 cases of juvenile or early onset parkinsonism (JP) and one case of pure akinesia was analysed. Improvement was obtained in about two thirds of the cases on symptoms of freezing in gait, difficulty of postural control, depressive mood and bradyphrenia. Severity of freezing in gait and that of the depressive mood were graded in five stage (from 0 to 4) scale and the improvement was evaluated by A (three stage improvement), B (two stage improvement), C (one stage improvement) and D (no change or worsened). Improvement of psychological symptoms was seen parallel to that of motor symptoms. It seems important that marked effect on both motor and psychological symptoms was obtained mostly in PD cases but not in the cases of JP. In MMPI test, depressive score (D) and hypochondriac score (Hs) were normalized in PD cases but not changed in JP, indicating differences in psychological traits between two groups. It was suggested that JP is a condition of mainly DA deficiency in nigro striatum but PD presents wider spectrum of symptoms covering both DA and NE deficiency. Importance of the role of aging of the brain in each individual patient is discussed and interpreted in relation to the difference of clinical pictures.

Aged↗

Effects of biogenic amine precursors on ovarian steroid-induced LH release in acutely ovariectomized rats.

Effects of catecholamines and indoleamine precursors on the luteinizing hormone (LH) release induced by estradiol (E2) and progesterone (P4) in acutely ovariectomized (Ovx) rats were studied. Rats were Ovx on diestrus day 1 (D1) and received a spaced injection of E2 and P4 on D1 and D2, respectively. One of the following substances: L-beta-3, 4-dihydroxyphenylalanine (L-DOPA), DL-threo-dihydroxyphenylserine (DOPS), or 5-hydroxy-L-tryptophan (5-HTP) was administered intraperitoneally at 0900h on the expected diestrus day 2 (D2). The control group received saline. Serial blood samples were collected in the afternoon of D2 and plasma concentrations of LH were measured by radioimmunoassay. Results indicate that E2 and P4-induced LH release could be facilitated, but not significantly, by DOPS, delayed/inhibited by L-DOPA, and completely inhibited by 5-HTP as compared with saline controls. Exogenous administration of luteinizing hormone releasing hormone (LHRH) induced significantly higher LH release in E2/P4-primed Ovx than in control Ovx rats. Results imply that the classical neurotransmitters in the central nervous system might modify the threshold of LHRH neurons in the hypothalamus.

5-Hydroxytryptophan↗